Entering text into the input field will update the search result below

Lilly signs development deal for ultra-rapid insulin

Dec. 19, 2014 10:50 AM ETEli Lilly and Company (LLY) StockLLYBy: Douglas W. House, SA News Editor
  • Eli Lilly (LLY -0.2%) and Lyon, France-based Adocia enter into a worldwide licensing collaboration to develop an ultra-rapid insulin, known as BioChaperone Lispro, for the treatment of type 1 and 2 diabetes. The product, currently in Phase 1b, utilizes Adocia's proprietary BioChaperone technology.
  • Under the terms of the agreement, Adocia will receive an upfront payment of $50M, up to $280M in potential development and regulatory milestones and up to $240M in sales milestones. Lilly is responsible for the future development, manufacturing and commercialization of BioChaperone Lispro and will reimburse Adocia for certain R&D expenses during the term of the contract.
  • The French firm retains the right to develop and license its insulin programs unrelated to prandial ultra-rapid insulin.

Recommended For You

More Trending News

About LLY Stock

SymbolLast Price% Chg
Market Cap
PE
Yield (TTM)
Rev Growth (YoY)
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
LLY--
Eli Lilly and Company